Payment overview · 2025
General Payments
$53.56
1 reported records · 1 companies
Healthcare provider profile · identity verified
Taylor Dayton
Allopathic & Osteopathic Physicians|Family Medicine · VINTON, VA · NPI 1316407489
Verified facts
What the public records show
CMS Open Payments records show Taylor Dayton received $53.56 in general payments during 2025 across 1 reported records.
Medtronic, Inc. accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$53.56 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $53.56 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 574 | 170 |
| Lisinopril | Lisinopril | 415 | 119 |
| Losartan Potassium | Losartan Potassium | 387 | 113 |
| Hydrochlorothiazide | Hydrochlorothiazide | 328 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 78 |
| Gabapentin | Gabapentin | 242 | 60 |
| Omeprazole | Omeprazole | 212 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 205 | 65 |
| Sertraline Hcl | Sertraline Hcl | 193 | 57 |
| Alendronate Sodium | Alendronate Sodium | 177 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 177 | 51 |
| Furosemide | Furosemide | 173 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 167 | 50 |
| Jardiance | Empagliflozin | 163 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 57 |
| Potassium Chloride | Potassium Chloride | 154 | 47 |
| Trazodone Hcl | Trazodone Hcl | 152 | 51 |
| Metformin Hcl | Metformin Hcl | 151 | 46 |
| Ozempic | Semaglutide | 151 | 29 |
| Carvedilol | Carvedilol | 149 | 42 |
| Metformin Hcl Er | Metformin Hcl | 139 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 133 | 42 |
| Bupropion Xl | Bupropion Hcl | 124 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 119 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 117 | 34 |
| Montelukast Sodium | Montelukast Sodium | 114 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 32 |
| Eliquis | Apixaban | 103 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 26 |
| Famotidine | Famotidine | 86 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 81 | 22 |
| Simvastatin | Simvastatin | 79 | 24 |
| Buspirone Hcl | Buspirone Hcl | 78 | 25 |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Allopurinol | Allopurinol | 64 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 23 |
| Prednisone | Prednisone | 63 | 53 |
| Ondansetron Odt | Ondansetron | 61 | 24 |
| Trulicity | Dulaglutide | 59 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Atenolol | Atenolol | 52 | 16 |
| Klor-Con M20 | Potassium Chloride | 52 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 14 |
| Nystatin | Nystatin | 48 | 31 |
| Glipizide | Glipizide | 47 | 17 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Spironolactone | Spironolactone | 46 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 44 | 11 |
| Mirtazapine | Mirtazapine | 43 | 11 |
| Meloxicam | Meloxicam | 42 | 23 |
| Cefadroxil | Cefadroxil | 41 | 36 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 30 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 12 |
| Alprazolam | Alprazolam | 32 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Clobetasol Propionate | Clobetasol Propionate | 32 | 12 |
| Finasteride | Finasteride | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 17 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 13 | 12 |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 12 |
| Colchicine | Colchicine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.56 · 1 records | Medtronic, Inc. | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error